National Pension Service Buys 10,529 Shares of Illumina, Inc. $ILMN

National Pension Service raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 29.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,284 shares of the life sciences company’s stock after acquiring an additional 10,529 shares during the period. National Pension Service’s holdings in Illumina were worth $4,396,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. grew its position in Illumina by 0.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after purchasing an additional 99 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Illumina by 8.9% in the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after buying an additional 111 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares in the last quarter. Archer Investment Corp grew its holdings in shares of Illumina by 12.9% during the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after buying an additional 123 shares during the last quarter. Finally, Bouvel Investment Partners LLC increased its position in shares of Illumina by 2.3% during the third quarter. Bouvel Investment Partners LLC now owns 6,129 shares of the life sciences company’s stock valued at $582,000 after acquiring an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.17% of the stock is owned by company insiders.

Illumina Stock Down 4.0%

ILMN stock opened at $135.43 on Wednesday. The company has a market cap of $20.69 billion, a price-to-earnings ratio of 30.37, a P/E/G ratio of 2.34 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The business’s 50-day moving average is $138.50 and its two-hundred day moving average is $115.74. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ILMN. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Guggenheim upped their price target on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. JPMorgan Chase & Co. lifted their price objective on Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Stifel Nicolaus boosted their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average target price of $127.18.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.